Plant‐Derived Vesicle‐Like Nanoparticles as Promising Biotherapeutic Tools: Present and Future
Extracellular vesicles (EVs) are heterogeneous, phospholipid bilayer‐enclosed biological
particles that regulate cell communication by molecular cargo delivery and surface signaling. …
particles that regulate cell communication by molecular cargo delivery and surface signaling. …
[HTML][HTML] Obesity survival paradox in pneumonia: a meta-analysis
W Nie, Y Zhang, SH Jee, KJ Jung, B Li, Q Xiu - BMC medicine, 2014 - Springer
… Statistical heterogeneity among studies was evaluated using the Q and I 2 statistics. For
the I 2 metric, we considered low, moderate and high I 2 values to be 25%, 50% and 75%, …
the I 2 metric, we considered low, moderate and high I 2 values to be 25%, 50% and 75%, …
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …
…, L Chen, M Ye, J Huang, X Zhi, Y Zhang, Q Xiu… - The lancet …, 2011 - thelancet.com
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis
W Nie, B Li, Q Xiu - Journal of Antimicrobial Chemotherapy, 2014 - academic.oup.com
… Statistical heterogeneity among studies was evaluated using the Q and I 2 statistics. Meta-regression
was used to assess the effect of age on treatment efficacy. Subgroup analyses and …
was used to assess the effect of age on treatment efficacy. Subgroup analyses and …
[HTML][HTML] Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced …
…, Y Luo, L Chen, M Ye, J Huang, X Zhi, Y Zhang, Q Xiu… - Annals of …, 2015 - Elsevier
Background The OPTIMAL study was the first study to compare efficacy and tolerability of
the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
[HTML][HTML] Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients …
…, Y Luo, L Chen, M Ye, J Huang, X Zhi, Y Zhang, Q Xiu… - Annals of …, 2013 - Elsevier
Background The OPTIMAL study found that erlotinib improved progression-free survival (PFS)
versus standard chemotherapy in Chinese patients with advanced EGFR mutation-…
versus standard chemotherapy in Chinese patients with advanced EGFR mutation-…
YKL-40 induces IL-8 expression from bronchial epithelium via MAPK (JNK and ERK) and NF-κB pathways, causing bronchial smooth muscle proliferation and …
…, Z Shi, H Huang, Z Fang, J Chen, Q Xiu… - The Journal of …, 2013 - journals.aai.org
Recently, the serum levels of YKL-40, a chitinase-like glycoprotein, have been shown to be
significantly elevated in asthmatics and are associated with asthma severity. Although these …
significantly elevated in asthmatics and are associated with asthma severity. Although these …
[HTML][HTML] Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis
W Nie, Y Zhang, J Cheng, Q Xiu - PloS one, 2012 - journals.plos.org
Background The benefit of corticosteroids in community-acquired pneumonia (CAP) remains
controversial. We did a meta-analysis to include all the randomized controlled trials (RCTs) …
controversial. We did a meta-analysis to include all the randomized controlled trials (RCTs) …
YKL-40 in asthmatic patients, and its correlations with exacerbation, eosinophils and immunoglobulin E
…, B Li, Z Shi, J Chen, T Zhang, Q Xiu - European …, 2010 - Eur Respiratory Soc
The chitinase-like protein YKL-40, which binds chitin but lacks chitinase activity, has been
found to be either the cause or a biomarker for asthma. The aim of our study was to investigate …
found to be either the cause or a biomarker for asthma. The aim of our study was to investigate …
[HTML][HTML] A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non …
B Han, Q Xiu, H Wang, J Shen, A Gu, Y Luo… - Journal of Thoracic …, 2011 - Elsevier
Introduction: Recombinant human endostatin is a novel inhibitor of tumor angiogenesis that
acts specifically on neovascular endothelial cells. Studies have shown that endostar plus …
acts specifically on neovascular endothelial cells. Studies have shown that endostar plus …